RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.93
+1.93%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$26.12
From 52W high−50.61%
Volume926599.00
Market cap$1.46B
P/E (TTM)—
P/S (TTM)73.0x
Div yield—
Key dataNov 4, 2026
Open
$26.12
From 52W high
−50.61%
Volume
926599.00
Market cap
$1.46B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.0x
P/E (TTM)
—
RSI (14)
41.1
MomentumView details →
1D Return
+1.93%
YTD Return
−14.09%
SummaryUpdated Jun 1, 2026
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts. The company was originally incorporated as Precision Neuroscience NewCo, Inc. before changing its name in October 2022. Rapport focuses on discovering and developing small molecule medicines to treat central nervous system disorders, representing a relatively young entrant in the competitive biotechnology sector with a specialized focus on neurological conditions.
Similar companies
Latest newsMore news →
Rapport Therapeutics, Inc. reported third-quarter 2026 financial results and stated that it had $815.4 million in cash and cash equivalents as of November 3, 2026, with a cash runway through the end of 2029.11h agoRapport Therapeutics closed an offering of $172.5 million aggregate principal amount of 2.25% convertible senior notes due 2032, including full exercise of the underwriters’ over-allotment option.2d agoRapport Therapeutics closed public offerings of 9,761,905 common shares and pre-funded warrants for up to 1,190,476 shares, alongside a concurrent private placement.2d ago